BIOAGE LABS, INC. Financing Cash Flow
BIOAGE LABS, INC. (BIOA) reported Financing Cash Flow of $139.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- BIOAGE LABS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $15.97M.
- BIOAGE LABS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $123.72M.
- BIOAGE LABS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $16.01M, a 35.70% decline year-over-year.
- BIOAGE LABS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$1.54M, a 100.81% decline year-over-year.
- BIOAGE LABS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $11.47M, a 96.99% decline from fiscal 2024.
- BIOAGE LABS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $381.20M, a 990.98% increase from fiscal 2023.
- BIOAGE LABS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $34.94M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $139.68M 10-Q · filed 2026-08-05 | $155.69M derived: sum of 3 quarters · filed 2026-08-05 | $154.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $123.72M 10-Q · filed 2026-05-08 | $139.73M derived: sum of 2 quarters · filed 2026-05-08 | $138.18M derived: sum of 3 quarters · filed 2026-05-08 | $136.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $16.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $14.47M derived: sum of 2 quarters · filed 2026-03-24 | $12.97M derived: sum of 3 quarters · filed 2026-08-05 | $11.47M 10-K · filed 2026-03-24 |
| 2025-09-30 | -$1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.04M derived: sum of 2 quarters · filed 2026-08-05 | -$4.54M 10-Q · filed 2025-11-06 | $20.36M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$3.00M 10-Q · filed 2026-08-05 | $21.90M derived: sum of 3 quarters · filed 2026-08-05 | $212.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$1.50M 10-Q · filed 2026-05-08 | $23.40M derived: sum of 2 quarters · filed 2026-05-08 | $214.09M derived: sum of 3 quarters · filed 2026-05-08 | $211.70M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $24.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $215.59M derived: sum of 2 quarters · filed 2026-03-24 | $213.20M derived: sum of 3 quarters · filed 2026-03-24 | $381.20M 10-K · filed 2026-03-24 |
| 2024-09-30 | $190.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $188.30M derived: sum of 2 quarters · filed 2025-11-06 | $356.30M 10-Q · filed 2025-11-06 | $355.29M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$2.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $165.61M 10-Q · filed 2025-08-06 | $164.60M derived: sum of 3 quarters · filed 2025-08-06 | |
| 2024-03-31 | $168.00M 10-Q · filed 2025-05-06 | $166.99M derived: sum of 2 quarters · filed 2025-05-06 | ||
| 2023-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $34.94M 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $35.95M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |